Profile: Maxygen, Inc. focuses on the development of protein therapeutics. Many natural proteins are currently being used to treat diabetes, anemia, hepatitis and cancer. Our products include maxy-G34, maxy- VII and maxy-4. Our maxy-G34 product candidate is an improved granulocyte colony stimulating factor (G-CSF) for the treatment of neutropenia. G-CSF is a natural protein that works by stimulating the body's bone marrow to produce more white blood cells. Neutropenia is a state where there is a severe decrease in neutrophil cell counts in the blood. Neutrophil is a specific type of blood cell that plays an important role in the defense against bacterial infections. Neutropenia is a common side effect of chemotherapeutic treatments such as breast cancer, lung cancer, lymphoma and leukemia. Our G-CSF product neupogen® and neulasta®, are used to treat chemotherapy and radiation-induced neutropenia. Our maxy-VII is a novel factor VIIa for the treatment of hemophilia. MolecularBreeding™ also known as gene shuffling, is an iterative process of recombination and selection. The products of these recombined genes (proteins) are screened for the targeted drug properties. This platform allows scientists to exploit gene variation that can result in unique drug targets.